menu ☰
menu ˟

FDA approves expanded indication for dapagliflozin in type 2 diabetes, kidney disease

27 Feb 2019
The FDA on Wednesday approved a label update for the SGLT2 inhibitor dapagliflozin, expanding its use for patients with type 2 diabetes and moderate renal impairment, according to a press release form Astra Zeneca.The expanded label indication is int...

Click here to view the full article which appeared in Endocrinology

Please note

The news articles accessible on the Health Well website have been compiled from various sources that are not controlled by the Institute of Public Health in Ireland (IPH). IPH is therefore not responsible for the content of external websites and the inclusion of a link to an external website from the Health Well should not be understood to be an endorsement of that website.